Brief: Amylyx Pharmaceuticals Q3 EPS USD -1.07 Vs. IBES Estimate USD -0.71
07/11/2024 12:00
Nov 07 (Reuters) - Amylyx Pharmaceuticals Q3 operating income USD -75.661 million vs. IBES estimate USD -52.2 million. * Q3 operating expenses USD 76.077 million * Q3 pretax profit USD -72.704 million * Q3 net income USD -72.704 million vs. IBES estimate USD -39.9 million
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock